Miranda F, Cedillo ZL, Sandoval SA, Hernández JC, Sánchez H, Velázquez-Martínez DN

Language: Spanish
References: 24
Page: 206-211
PDF size: 83.51 Kb.

ABSTRACT

Introduction: Drug of abuse, such as amphetamine, share the ability to activate the mesolimbic dopamine (DA) system. The behavioral effects of amphetamine are mediated in large part by increasing DA neurotransmission in the nucleus accumbens. However, there is evidence that the glutamate (Glu) system may be able to regulate forebrain DA function. Objective: The present study examined the effects of mGluR5 6-methyl-2-(phenylethynyl)pyridine antagonist MPEP on the discriminative stimulus properties of amphetamine using conditioned taste aversion (CTA) as the drug discrimination procedure. Method: Male Wistar rats were deprived of water and trained in the CTA procedure. They received the administration of amphetamine (1.0 mg/kg) before a 10 min period of saccharin access that was followed by an injection of LiCl; on alternate days, subjects received saline before and after the access to saccharin. After rats learned amphetamine-saline discrimination, amphetamine was substituted by different doses of amphetamine or MPEP antagonist and amphetamine. Results: It was observed that the MPEP antagonist reduced the discriminative signal of amphetamine. Conclusions: These data suggest that the Glu system plays an important role in the discriminative properties of amphetamine.

REFERENCES

1. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21: 467-76.

2. Koe BK. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J Pharmacol Exp Ther 1976; 199: 649-61.

3. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003; 479: 23-40.

4. Groves PM, Rebec GV. Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs. Ann Rev Psychology 1976; 129: 91-127.

5. Kalivas PW. A role for glutamate transmission in addiction to psychostimulants. Addiction Biol 2000; 5: 325-39.

6. Wang JQ, McGinity JF. Glutamate-dopamine interactions mediate the effects of psychostimulant drugs. Addic Biol 1999, 4: 141-50.

7. Uzbay IT, Wallis CJ, Lal H, Forster MJ. Effects of NMDA receptor blockers on cocaine-stimulated locomotor activity in mice. Behav Brain Res 2000; 108: 57-61.

8. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, Conquet F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001; 4: 873-4.

9. Lee B, Platt DM, Rowlett, JK, Adewale AS, Spealman RD. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 6-methyl-2-(phenylethynyl)pyridine in squirrel monkeys: comparison with dizocilpine. J Pharmacol Exp Ther 2005; 312: 1232-40.

10. McGeehan AJ, Janak PH, Olive MF. Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, D-amphetamine and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology 2004; 174: 266-73.

11. Colpaert F. Drug discrimination in neurobiology. Pharmacol Biochem Behav 1997; 64: 337-45.

12. Kamien JB, Bickel WK, Hughes JR, Higgins ST, Smith BJ. Drug discrimination by humans compared to nonhumans: Current status and future directions. Psychopharmacology 1993; 111: 259-70.

13. Schuster CR, Johanson CE. Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Colpaert FC, Balster RL eds. Psychopharmacology, Series 4: Transduction Mechanisms of Drug Stimuli. Berlin: Springer; 1988, p. 161-75.

14. Miranda F, Velázquez-Martínez D. Discriminative stimulus properties of amphetamine in a conditioned taste aversion paradigm. Behav Pharmacol 1997; 8: 458-64.

15. Miranda F, Hermosillo A, Sánchez H, Velázquez-Martínez DN. Mecanismos no dopaminérgicos en las propiedades discriminativas de la anfetamina: efectos de agonistas serotoninérgicos. Rev Mex Psicol 2005; 22(2): 553-9.

16. Miranda F, Hong E, Velázquez-Martínez DN. Discriminative stimulus properties of indorenate in a conditioned taste aversion (CTA) paradigm. Pharmacol Biochem Behav 2001; 68: 427-33.

17. Pietraszek M, Rogo Z, Wolfarth S, Ossowska K. Opposite influence of MPEP, an mglur5 antagonist, on the locomotor hyperactivity induced by PCP and amphetamine. J Physiol Pharmacol 2004; 55(3): 587-93.

18. Herzig V, Schmidt WJ. Effects of MPEP on locomotion, sensitization and conditioned reward induced by cocaine or morphine. Neuropharmacology 2004; 47: 973-84.

19. McGeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drug of abuse. Synapse 2003; 47: 240-2.

20. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999; 38: 1493-503.

21. Romano C, Sesma MA, McDonald CT, O’Malley K, Van den Pol AN, Olney JW. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 1995; 355: 455-69.

22. Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 2004; 25(5): 265-72.

23. Meredith GE, Pennartz CMA, Groenewegen HJ. The cellular framework for chemical signaling in the nucleus accumbens. Prog Brain Res 1993; 99: 3-24.

24. Sesack SR, Pickel VM. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res 1990; 527: 266-79.